About Us
Science Programs
Pipeline
Clinical Trials
Careers
cONTACT
Resources
Corporate Presentation
Posters, PRESENTATIONS & Publications
MEDIA
Events
News & press releases
Investors
Overview
Stock Information
Analyst Coverage
Stock Quote & Chart
Historical Price Lookup
Investment Calculator
Financials & SEC FILINGS
Sec Filings
Quarterly Results
cORPORATE GOVERNANCE
Management Team
Board of Directors
Committee Composition
Governance Documents
EVENT DETAILS
< Back to All Events
AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
December 19, 2021 10:00 AM
Click here for webcast
Description
Supporting materials
There are no supporting documents for this event
Milademetan is a potent MDM2 inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cells
VIEW DOCUMENT
a
The MDM2 inhibitor milademetan induces synthetic lethality in GATA3 mutant, ER positive breast cancer
VIEW DOCUMENT
a
MDM2 gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan
VIEW DOCUMENT
a
VIEW DOCUMENT
a
< Back to All Events
